Skip to content
Screener

Bristol-Myers Squibb BMY Other Non-Current Assets

Other Non-Current Assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.27B
Incyte logo
IncyteINCY
$86.76M+167%
Gilead Sciences logo
Gilead SciencesGILD
$295M-20.1%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$103K0.0%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$20.1M-8.6%
Cytokinetics logo
CytokineticsCYTK
$19.41M+33.3%

Other financials

Income statement

See full
Revenue$13.0B+5.7%
Gross profit$9.2B+3.9%
Net income$3.3B+153%
EPS (diluted)$1.62+153%

Balance sheet

See full
Cash & equivalents$8.7B-30.8%
Total debt$43.3B-12.3%
Total equity$22.3B+28.0%
Total assets$87.6B-7.4%

Cash flow

See full
Operating cash flow$3.4B-13.4%
CapEx$305.0M-15.5%
Free cash flow$3.1B-13.2%

Valuation

See full
Market cap$129.98B+42.5%
Enterprise value$164.58B+28.6%
P/E14×-4.3×
P/S2.6×+0.7×

Profitability

See full
Gross margin70.2%-0.1pp
Net margin18.9%+8.4pp
FCF margin23.3%-7.3pp

Returns & leverage

See full
Return on equity46.7%+17.8pp
Debt / equity1.9×-0.9×
Current ratio1.5×+0.3×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 11:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000014272-26-000020
ASSETSJune 30,2026December 31,2025
Other intangible assets17,38719,103
Deferred income taxes5,3625,378
Marketable debt securities397396
Other non-current assets6,3786,474
Total Assets$87,634$90,038
LIABILITIES
Current liabilities:
Short-term debt obligations$1,027$2,261

Item 1. FINANCIAL STATEMENTS

FAQ

What is Bristol-Myers Squibb's other non-current assets?
Bristol-Myers Squibb (BMY) reported other non-current assets of $6.38B in Q2 2026.
How has Bristol-Myers Squibb's other non-current assets changed year-over-year?
Bristol-Myers Squibb's other non-current assets increased by 7.4% year-over-year, from $5.94B to $6.38B.
What is the long-term trend for Bristol-Myers Squibb's other non-current assets?
Over 5 years (2020 to 2025), Bristol-Myers Squibb's other non-current assets has grown at a 69.8% compound annual growth rate (CAGR), from $458M to $6.47B.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Bristol-Myers Squibb's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude